NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free NRIX Stock Alerts $12.36 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$12.17▼$12.6150-Day Range$9.87▼$17.4852-Week Range$4.22▼$18.12Volume599,965 shsAverage Volume1.30 million shsMarket Capitalization$607.49 millionP/E RatioN/ADividend YieldN/APrice Target$21.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nurix Therapeutics alerts: Email Address Nurix Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside72.6% Upside$21.33 Price TargetShort InterestBearish14.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$100,256 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.15) to ($3.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.14 out of 5 starsMedical Sector625th out of 913 stocksPharmaceutical Preparations Industry284th out of 425 stocks 4.4 Analyst's Opinion Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNurix Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.32% of the outstanding shares of Nurix Therapeutics have been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 1.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRIX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Nurix Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $100,256.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Nurix Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from ($3.15) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -4.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -4.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Nurix Therapeutics Stock (NASDAQ:NRIX)Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Read More NRIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRIX Stock News HeadlinesApril 19, 2024 | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Shares Gap Up to $14.65April 18, 2024 | stockhouse.comNurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesApril 28, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 17, 2024 | msn.comNurix Therapeutics (NRIX) Price Target Increased by 5.58% to 25.09April 15, 2024 | msn.comNurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating ExpectationsApril 15, 2024 | seekingalpha.comNurix Therapeutics Advances Promising Protein Degraders For B-Cell MalignanciesApril 12, 2024 | marketwatch.comShares of Nurix Therapeutics Down 6% on Plans for Stock SaleApril 12, 2024 | seekingalpha.comNurix Therapeutics prices upsized stock offering to raise $175 millionApril 28, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 11, 2024 | markets.businessinsider.comNurix Therapeutics Announces $125 Mln Public Stock Offering; Stock Down In After-hoursApril 11, 2024 | globenewswire.comNurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingApril 11, 2024 | globenewswire.comNurix Therapeutics Announces Proposed Public OfferingApril 10, 2024 | finanznachrichten.deNurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateApril 10, 2024 | markets.businessinsider.comNurix Therapeutics, Inc. Q1 Loss increases, but beats estimatesApril 10, 2024 | finance.yahoo.comNurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024April 10, 2024 | msn.comNRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024April 10, 2024 | globenewswire.comNurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateApril 9, 2024 | marketwatch.comNurix Therapeutics Shares Climb 19% on Extended Sanofi CollaborationApril 9, 2024 | globenewswire.comNurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesApril 9, 2024 | globenewswire.comNurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6April 3, 2024 | globenewswire.comNurix Therapeutics to Participate in Upcoming Investor ConferencesApril 2, 2024 | markets.businessinsider.comNurix Therapeutics Earns ‘Buy’ Rating on Strong Partnerships and Revenue PotentialApril 2, 2024 | markets.businessinsider.comCritical Insights From Nurix Therapeutics Analyst Ratings: What You Need To KnowApril 2, 2024 | finance.yahoo.comNurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesApril 2, 2024 | markets.businessinsider.comNurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two YearsApril 2, 2024 | globenewswire.comNurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesMarch 25, 2024 | globenewswire.comNurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)See More Headlines Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/28/2024Next Earnings (Estimated)7/11/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRIX CUSIPN/A CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees284Year FoundedN/APrice Target and Rating Average Stock Price Target$21.33 High Stock Price Target$31.00 Low Stock Price Target$10.00 Potential Upside/Downside+72.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,950,000.00 Net Margins-178.93% Pretax Margin-178.82% Return on Equity-67.08% Return on Assets-43.62% Debt Debt-to-Equity RatioN/A Current Ratio2.86 Quick Ratio2.86 Sales & Book Value Annual Sales$76.99 million Price / Sales7.89 Cash FlowN/A Price / Cash FlowN/A Book Value$3.43 per share Price / Book3.60Miscellaneous Outstanding Shares49,150,000Free Float45,612,000Market Cap$607.49 million OptionableOptionable Beta2.06 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Arthur T. Sands M.D. (Age 62)Ph.D., CEO, President & Director Comp: $986.32kMr. Johannes Van Houte (Age 58)Chief Financial Officer Comp: $681.98kDr. Gwenn M. Hansen Ph.D. (Age 53)Chief Scientific Officer Comp: $702.75kDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardMr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardDr. Arthur Weiss M.D.Ph.D., Founder & Member of Scientific Advisory BoardRita KwongSenior Accounting ManagerDr. Christine Ring J.D. (Age 59)Ph.D., Chief Legal Officer, Secretary & Chief Compliance Officer Comp: $595.83kMr. Eric C. Schlezinger J.D. (Age 57)Chief People Officer Dr. Jason Kantor Ph.D.Chief Business OfficerMore ExecutivesKey CompetitorsDianthus TherapeuticsNASDAQ:DNTHPureTech HealthNASDAQ:PRTCBicycle TherapeuticsNASDAQ:BCYCEvolusNASDAQ:EOLSSilence TherapeuticsNASDAQ:SLNView All CompetitorsInsiders & InstitutionsWasatch Advisors LPSold 1,512,992 shares on 4/18/2024Ownership: 2.516%Los Angeles Capital Management LLCSold 23,680 shares on 4/5/2024Ownership: 0.208%Wellington Management Group LLPBought 60,271 shares on 3/5/2024Ownership: 0.420%Houte Hans VanSold 6,812 sharesTotal: $68,256.24 ($10.02/share)Wasatch Advisors LPSold 814,871 shares on 2/14/2024Ownership: 5.670%View All Insider TransactionsView All Institutional Transactions NRIX Stock Analysis - Frequently Asked Questions Should I buy or sell Nurix Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NRIX shares. View NRIX analyst ratings or view top-rated stocks. What is Nurix Therapeutics' stock price target for 2024? 6 brokerages have issued 1 year target prices for Nurix Therapeutics' stock. Their NRIX share price targets range from $10.00 to $31.00. On average, they expect the company's stock price to reach $21.33 in the next year. This suggests a possible upside of 72.6% from the stock's current price. View analysts price targets for NRIX or view top-rated stocks among Wall Street analysts. How have NRIX shares performed in 2024? Nurix Therapeutics' stock was trading at $10.32 at the beginning of the year. Since then, NRIX shares have increased by 19.8% and is now trading at $12.36. View the best growth stocks for 2024 here. When is Nurix Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024. View our NRIX earnings forecast. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) posted its quarterly earnings data on Thursday, February, 15th. The company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.26. The business earned $15.16 million during the quarter, compared to analysts' expectations of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative trailing twelve-month return on equity of 67.08%. What ETFs hold Nurix Therapeutics' stock? ETFs with the largest weight of Nurix Therapeutics (NASDAQ:NRIX) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Range Cancer Therapeutics ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Loncar China Biopharma ETF (CHNA).iShares Genomics Immunology and Healthcare ETF (IDNA). What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR). When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Nurix Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (2.52%) and Los Angeles Capital Management LLC (0.21%). Insiders that own company stock include Christine Ring, Gwenn Hansen, Houte Hans Van, Pierre Beaurang and Stefani Wolff. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRIX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
